Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2008-04-29
2008-04-29
Landsman, Robert S. (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C435S069520, C435S071100, C435S252300, C536S023520
Reexamination Certificate
active
10650365
ABSTRACT:
This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods to produce recombinant super-compound interferon or its equivalent and various uses of said interferon.
REFERENCES:
patent: 4672108 (1987-06-01), Kung et al.
patent: 4681930 (1987-07-01), Kung et al.
patent: 4695623 (1987-09-01), Stabinsky
patent: 4897471 (1990-01-01), Stabinsky
patent: 5602232 (1997-02-01), Reichert et al.
patent: 5874304 (1999-02-01), Zolotukhin et al.
patent: 5972331 (1999-10-01), Reichert et al.
patent: 6087478 (2000-07-01), Vinkemeier et al.
patent: 6114145 (2000-09-01), Olsen et al.
patent: 6532437 (2003-03-01), Clardy et al.
patent: 6546074 (2003-04-01), Blundell et al.
patent: 6579695 (2003-06-01), Lambalot et al.
patent: 2003248419 (2003-11-01), None
patent: 1375502 (2002-11-01), None
patent: 1478545 (2004-03-01), None
patent: 0083734 (1982-12-01), None
patent: 422697 (1991-04-01), None
patent: 0777495 (1995-10-01), None
patent: 0736303 (1996-03-01), None
patent: WO 2005/021777 (2005-03-01), None
patent: WO 2005/034853 (2005-04-01), None
patent: WO 2006/134497 (2006-12-01), None
Day et al. Engineered Disulfide Bond Greatly Increases Specific Activity of RecombinNT Murine Interferon-beta (1992), J. of Interferon Res. 12, pp. 139-143.
Nasoff, M. High-Level Expression of Human Genes inE. coli. (1999), Expression vol. 6, No. 2, pp. 10-11.
PCT Notification of Transmittal of International Preliminary Report on Patentability for Huiyangtech (USA) Inc., Int'l Application No. PCT/US04/28068, Filed Aug. 26, 2004, Dated May 13, 2005.
EPO Supplementary European Search Report, Application No. EP 02702211, Filed Feb. 28, 2002, Date of completion of the search: Feb. 23, 2005.
Apeler H, et al. “Expression of natural and synthetic genes encoding herpes simplex virus 1 protease inEscherichia coliand purification of the protein”, European Journal Of Biochemistry / Febs. Aug. 1, 1997, vol. 247, No. 3, Aug. 1 1997, pp. 890-895, XP002318941, ISSN: 0014-2956.
Guzman Luz-Maria, et al. “Tight regulation, modulation, and high-level expression by vectors containing the arabinose P-BAD promoter”, Journal of Bacteriology, vol. 177, No. 14, 1995, pp. 4121-4130, XP002121022, ISSN: 0021-9193.
Huang Wanzhi, et al. “Use of the arabinose pbad promoter for tightly regulated display of proteins on bacteriophage”, Gene (Amsterdam), vol. 251, No. 2, Jun. 27, 2000, pp. 187-197, XP004206676, ISSN: 0378-1119.
International Publication No. WO 93/21229 for Amgen Inc et al., Published Oct. 28, 1993. PCT/US93/04471 “Methods and Compositions for the Treatment of Diseases with Interferon While Reducing Side Effects”.
International Publication No. WO 83/04053 for Amgen Inc et al., Published Nov. 24, 1983. PCT/US83/00605 “The Manufacture and Expression of Large Structural Genes”.
International Publication No. WO/02/80958 for Guangwen Wei, Published Oct. 17, 2002. PCT/CN02/00128 “Recombination Super Compound Interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibitor”.
U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/927,975, Filed Aug. 26, 2004, Dated Sep. 19, 2007.
Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 12, 2005.
Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Jun. 1, 2006.
Australian Notice of Acceptance for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 18, 2006.
European Communication for Sichuan Biotechnology Research Center, European Application No. 02702211.D, Filed Sep. 25, 2003, Dated Dec. 14, 2006.
Indian Examination Report for Sichuan Biotechnology Research Center, Indian Application No. 279/MUM/2004, Filed Mar. 5, 2004, Dated Aug. 2, 2007.
Malaysian Examiner's Report for Sichuan Biotechnology Research Center, Malaysian Application No. PI 20033246, Filed Aug. 28, 2003, Dated Mar. 8, 2007.
Singapore Written Opinion for Huiyangtech (USA), Inc., Singapore Application No. 200601204-1, Filed Feb. 23, 2006, Dated Jul. 19, 2007.
Taiwanese Office Action for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Sep. 21, 2006.
Taiwanese Formal Rejection for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Dec. 29, 2006.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority (International Search Report and Written Opinion included), Application No. PCT/IB2006/002340, Filed Mar. 9, 2006, Dated May 10, 2007.
International Search Report, Application No. PCT/US2004/028067 for Huiyangtech, Inc., “Uses of interferons with altered spatial structure,”Filed Aug. 26, 2004, Dated Feb. 27, 2006, Date of Completion of the Search: Nov. 2, 2005.
International Search Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, “Recombination Super Compound interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibito,” Filed Feb. 28, 2002, Dated Aug. 8, 2002, Date of Completion of the Search: Jul. 23, 2002.
International Preliminary Examination Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, “Recombination Super Compound Interferon Used as Helatitis B Surface Antigen and E Antigen Inhibitor,” Filed Feb. 28, 2002, Dated Feb. 15, 2004.
Written Opinion of the International Searching Authority for International Application No. PCT/US04/28068, filed Aug. 26, 2004 for Huiyangtech (USA) Inc., dated Mar. 4, 2004.
International Search Report for International Application No. PCT/US04/28068, filed Aug. 26, 2004 for Huiyangtech (USA) Inc., dated Mar. 4, 2005.
Ivan Amato, Jan. 22, 2007, “Silent No Longer: Researchers Unearth Another Stratum of Meaning in the Genetic Code,” Chemical and Engineering News, 85(4):38-40.
Ausubel et al., Eds., 1999, Chapter Ten, “Analysis of Proteins,” form Short Protocols in Molecular Biology, 4th ed., pp. 10-1 to 10-8.
Cinatl et al., 2003, “Treatment of SARS with Human Interferons,” The Lancet, 362:293-294.
Day et al., 1992, “Engineered disulfide bond greatly increases specific activity of recombinant murine interferon-beta,” Journal of Interferon Res., 12: 139-143.
Duan et al., 2003, “Anti-SARS virus activities of different recombinant human interferons in cell culture system,” Chinese J. Clin. Virol., 17(3):205-208.
Higgins et al., 1983, “Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers,” Antimicrobial Agents and Chemotherapy, 24(5):713-715.
Holland, C.C. and T.L. Wright, 1994, “New approaches to treatment of chronic viral hepatitis,” Pathology (Phila.), 3(1).
Nackley, A.G. et al., Dec. 22, 2006, “Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure,” Science, 314:1930-1932.
Nasoff et al., 1999, “High-level expression of human genes in E. coli,” Expression, 6(2): 10-11.
Pyrc, K, et al., 2007, “Antiviral strategies against human coronaviruses,” Infectious Disorders - Drug Targets, 7:59-66.
Zhao, Z. et al., 2003, “Description and Clinical treatment of an early outbreak of severe Acute Respiratory Syndrome (SARS) in Guangzhou, PR China,” Journal of Med. Microbiol., 52:715-720.
U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/927,975, Filed Aug. 26, 2004, Dated Apr. 3, 2007.
U.S. Off
Guo Rongbing
Wei Guangwen
Zhang Renhuai
Hissong Bruce D.
Landsman Robert S.
Law Offices of Albert Wal-Kit Chan, PLLC
Sichuan Biotechnology Research Center
LandOfFree
Recombinant super-compound interferon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant super-compound interferon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant super-compound interferon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3914347